The abstract is read at the publisher; the summary is JClub's.
TP53 pathogenic variants predict worse overall survival in advanced endometrial carcinoma (HR 1.61, 95% CI 1.23–2.10) and clear cell ovarian carcinoma (HR 3.23, 1.05–9.89), but not overall high-grade serous ovarian carcinoma.
- Why it matters: Prognostic effects of TP53 and other pathogenic variants may differ by organ and tumor subtype, limiting accurate risk stratification for advanced Mullerian cancers.
- What they did: Next-generation sequencing was used in 1060 stage III–IV ovarian and 543 endometrial carcinoma cases, with overall survival assessed by multivariable Cox regression and fixed-effect pooling across organs; public cBioPortal cohorts (including The Cancer Genome Atlas) were used for testing in 8881 tumors.
- The result: RB1 pathogenic variants were linked to worse survival across both organs (pooled HR 1.47, 1.05–2.06), while TP53 effects varied by histology and co-occurring KRAS PV status.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.